Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Morphogen-IX Ltd.
Centessa ‘Creates Pharma Pipeline Overnight’ Using Novel R&D Approach
With $250m in series A funding, Cambridge, MA-based Centessa is looking to upend traditional biopharma R&D models. The new company was created through the merger of 10 private biotechs, which will sit under the Centessa umbrella as subsidiaries.
Centessa Looks To Transform Drug Development With ‘Asset Centric’ Model
In an interview with Scrip, CEO Saurabh Saha elaborates on the first-of-its-kind R&D model.
CIC Raises £150M To Reinforce Cambridge Ecosystem
Cambridge Innovation Capital completes £150m fundraising to give it more firepower to reinforce Cambridge, UK’s pre-eminent status as Europe’s leading life sciences and tech hub.
Finance Watch: Relay Raises $400m – And It's Only The Third-Largest Biopharma VC Round Of 2018
The company isn't relaying any details about its drug targets, but will use the mega-round to take its first candidates into the clinic. Also, RiverVest raises a $184.4m VC fund, Annexon closes a $75m Series C, Takeda lists its stock in the US, and Aptorum goes public.
Drug Discovery Tools
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.